– USA, MA – i2o Therapeutics, Inc. today announced the appointment of current Executive Chairman Kurt Graves as Chairman, President, and CEO, succeeding Dr. Ravi Srinivasan as CEO.
About Kurt Graves
Kurt Graves has provided leadership to several highly innovative biotech and global pharmaceutical companies over the last 30 years. He has served as Chairman, President, and CEO of Intarcia Therapeutics, former Chairman of Radius Health, former Executive Chairman of i2o Therapeutics, and as a Board member at Achillion Pharmaceuticals until it was acquired, and at Seres Health. He was also E&Y’s New England Entrepreneur of the Year in 2015. Previously, Mr. Graves served as EVP, Head of Corporate Development, Strategic Drug Development and Program Management, and Head of Commercial at Vertex Pharmaceuticals. Before that, he was at Novartis Pharmaceuticals for nearly 10 years, most recently as the Global Head of the General and Specialty Medicines Business and the first Global CMO for the Pharmaceuticals division. Earlier in his career, at Merck and Astra-Merck for nearly 10 years, he worked on multiple cardiovascular and GI medicines and led the GI Business Unit responsible for developing and commercializing Prilosec, Nexium, and Prilosec OTC.
About i2o Therapeutics
i2o Therapeutics is a private biotechnology company that was founded in 2019 to exploit the versatile properties of ionic liquids for producing oral biologics and peptides. i2o has also acquired wholly-owned proprietary peptides with the intent to advance novel therapies for serious cardiometabolic diseases. As a complement to the oral ionic liquids approach, i2o also owns the rights to a sustained delivery system (small osmotic implants – Medici) that enables just twice-yearly maintenance dosing of chronic medications. With this scope of platform technologies and proprietary peptides, i2o’s initial aim is to form strategic partnerships and to advance meaningful innovations that achieve a new standard of care for patients suffering from T2DM, Obesity, and related diseases. Over time, i2o’s platforms will also be leveraged for other opportunities and collaborations.
The company has completed a series of corporate and strategic transactions including:
- A $46 million Series A financing with top-tier biotech investors.
- Acquisition and integration of proprietary pipeline assets in the cardiometabolic space from Intarcia Therapeutics including long-acting GLP-1s, Amylin, Glucagon, and PYY. The combination of long-acting GLP-1s and the other peptides noted holds significant potential to redefine the standards of care in diabetes, obesity, and related indications.
- An acquisition and integration of ITCA 650 and the Medici implant technology platform which is an investigational twice-yearly implantable GLP-1 for type 2 diabetes was recently granted a public hearing on September 21 before an FDA Advisory Committee. The public hearing was granted by the Commissioner’s Office and FDA’s Chief Scientist.
- i2o has also entered into a new 4-year sponsored research and licensing agreement with the Mitragotri Lab at Harvard University to further strengthen its IP and leadership position in the Ionic Liquid space where additional ionic liquid uses and applications are being advanced.
SOURCE: https://i2obio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.